DiaSorin has received Food and Drug Administration (FDA) clearance for its LIAISON® Epstein-Barr Virus (EBV) assays, including VCA IgM, VCA IgG, and EBNA IgG. The company introduced its first line of EBV ELISA tests in 1989, and currently serves regional reference laboratories in the United States.
“We are proud to be the first to market with an automated method for EBV testing,” says Stephen P. Gouze, president and general manager of DiaSorin Inc. “LIAISON offers the only Epstein-Barr Virus assay in an automated, random access chemiluminescence platform. It provides the same consistent results physicians have seen from DiaSorin’s ELISA assays since 1989. Patients will benefit from rapid results—35 minutes to first results—and the world-class assay reliability of the LIAISON system. Laboratories will benefit from high throughput—up to 90 results per hour—and complete walkaway automation.”
More than 1,000 LIAISON systems are in use worldwide with a menu of more than 50 diagnostic tests, including bone and mineral, infectious disease, autoimmune, and hepatitis assays. DiaSorin will add these and other assays in the United States as FDA clearance is received.
DiaSorin Inc
(800) 328-1482; www.diasorin.com
